Expression Services, Protein Purification Services, and Antibody Therapeutics Development.
Specialties and Expertise:Immunoadhesins, Protein Expression Services, Protein Purification Services, Antibody Therapeutics
Development, Biodefense, Middle East Respiratory Syndrome (MERS), IgG Antibodies, Nanobodies, Recombinant Protein, Imm... read more
Size and Minority Status
- Products and services 2
- Сommodity codes 11
MERS-CoV with DPP4 on human cells and thus prevent infection.
DPP4-Fc is an immunoadhesin that could be used as a 'receptor decoy' to block the interaction of MERS-CoV with DPP4 on human cells and thus prevent infection.
Middle East respiratory syndrome coronavirus MERS CoV is a newly emerging human health threat with a case fatality rate. MERS CoV uses dipeptidyl peptidase DPP a cell surface protein to enter and infect cells. During our Phase I study using a transient plant expression system we produced fusions of human DPP and the human immunoglobulin Fc sequences of IgG IgA and IgA to produce receptor decoys and to block cellular infection with MERS Co. We demonstrated that DPP Fc binds to the S domain of MER read more
Middle East Respiratory Syndrome, MERS coronavirus (MERS-CoV) causes a severe acute respiratory illness with a high fatality rate among reported cases MERS was first reported in but the virus has been circulating in camels which are thought to be an animal reservoir for at least years. To date over, MERS cases have been reported to the World Health Organization including over deaths. While most cases have been in Saudi Arabia and contact with camels or camel products has been implicated in some read more
immunoglobulin G to neutralizes anthrax toxin and offer protection against Bacillus anthracis.
CMG2-Fc (PBI-220) is an Immunoadhesin composed of CMG2 and the Fc region of human immunoglobulin G to neutralizes anthrax toxin and offer protection against Bacillus anthracis.
Planet Biotechnology Inc. (PBI) is developing a therapeutic recombinant protein, PBI-220, that neutralizes anthrax toxin in vitro and protects against inhalational anthrax in vivo. PBI uses transgenic plants as an innovative, economical and flexible production technology. Our therapeutic protein, a fusion of the high- affinity human anthrax toxin receptor CMG2 and the Fc portion of IgG, offers broad-spectrum protection against anthrax because it can neutralize not only wild-type anthrax toxin bu read more
to successfully manufacture pilot-scale quantities
of neutralizing anti-botulinum toxin antibodies in...
considerable case fatality rate caused by
toxigenic Corynebacteria. Diphtheria toxin (DT) ...
methods for the production of functional
therapeutic antibodies and immunoadhesin in ...
coronavirus (MERS-CoV) causes a severe acute
respiratory illness with a high fatality rate amon...
Locations Served 2
Public Spend Forum compiles the information shown in GovShop's supplier profiles based on multiple sources and relies on GovShop's supplier and buyer user community to help validate the information. We recommend conducting further due diligence and research to validate the information if accuracy is critical.